Post-earnings recap
Reported
Thu, Aug 13, 2026
EPS actual
$-0.54
EPS est.
$-0.73
EPS surprise
+26.03%
1-day move
-7.07%
Belite Bio's earnings report shows a significant increase in net loss year-over-year, which may raise concerns among investors. The acceptance of the NDA for tinlarebant is a positive development, but the lack of revenue reporting and the drop in stock price by over 7% suggest that investors are cautious about the company's immediate financial health and future prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.54 | N/A | +26.03% |
| Revenue | N/A | N/A | N/A |
| Net Loss | $28.4M | N/A | N/A |
| R&D Expenses | $18.2M | N/A | N/A |
| Cash Equivalents | $780M | N/A | N/A |
Management expressed cautious optimism regarding the acceptance of their NDA by the FDA. They highlighted the increase in R&D expenses due to milestone-related payments.
The FDA accepted the NDA for tinlarebant in Stargardt disease, with a PDUFA date of February 12, 2027.
R&D expenses increased primarily due to a royalty payment related to a milestone.
Belite Bio, Inc. is a pharmaceutical company focused on developing innovative treatments for metabolic and retinal diseases. As part of the health care sector, its advancements could significantly impact patient care and the pharmaceutical landscape.
Last quarter
In Q1 2026, Belite Bio reported an EPS of -$0.34, surpassing analyst expectations by 42.86%. The stock reacted positively, gaining 2.62% the following day.
EPS beat streak
3Q
EPS beat rate
50%
Avg EPS surprise
+4.11%
Avg 1-day reaction
-0.39%
Investors are cautiously optimistic about Belite Bio's upcoming earnings, especially after the positive surprise last quarter. However, the lack of analyst estimates adds uncertainty.
Bull case
If the company continues to beat EPS expectations and shows signs of revenue growth, it could lead to increased investor confidence and a higher stock price.
Bear case
Conversely, if the earnings report reveals larger-than-expected losses or stagnation in revenue, it could lead to a sell-off as investors reassess the company's growth potential.
The print will turn on these.
Q1
What will the EPS be for Q2-2026, and how does it compare to previous quarters?
Given the company's recent performance, a strong EPS could signal continued improvement, while a weak result may raise concerns about profitability.
Q2
What insights can management provide on revenue growth and future product development?
Understanding the company's growth trajectory and pipeline can help investors gauge its long-term potential.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±17.3%
Why consensus could be wrong
The market may be underestimating Belite Bio's potential for revenue growth based on recent product developments and partnerships, which could lead to a stronger-than-expected performance this quarter.
Supporting evidence
The company's recent EPS surprise indicates operational improvements that may not be fully reflected in market expectations.
Options pricing suggests a significant move, indicating that traders anticipate volatility, which may not align with a cautious consensus.
Key risk
If the EPS exceeds -$0.30, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it will either reinforce the company's recovery narrative or highlight ongoing challenges.
Bull confirmed if
An EPS of -$0.30 or better, along with indications of revenue growth, would confirm the bull case.
Bear confirmed if
An EPS worse than -$0.50 could validate the bear case.
What the market is pricing for the move.
Implied Move
±20.33%
Historical Avg
±3.2%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±20.3% while BLTE has averaged ±3.2% over the last 8 prints — setup is pricing rich.
30d HV
38.6%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 14 of 29 (48%)
This setup has occurred 30 times across Health Care in the last 2 years. 14 of 29 faded and 15 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.7%, with a raw directional average of +3.1% (modestly positive historical bias).
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$82,658.89
500 sh
1 insider
Net
$82,658.89
Net selling
Most Active Insiders· 8 open-market trades
$82,658.89
Net selling
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Belite Bio beats expectations, history suggests a potential stock increase of around 2.36%, confirming a positive outlook.
In line / cautious
If results are in line but management's commentary is cautious, the stock may remain flat or see a slight decline as investors digest the news.
Miss
Should the company miss expectations, history indicates a potential drop of around 1.06%, leading to increased scrutiny on its future prospects.
The lines on the call that would change the story.
Recent Transactions
Oct 1, 2026 · @ $163.63
200 sh
$32,725.00
Oct 1, 2026 · @ $165.49
120 sh
$19,859.22
Oct 1, 2026 · @ $167.59
78 sh
$13,071.83
Oct 1, 2026 · @ $166.44
50 sh
$8,321.84
Oct 1, 2026 · @ $164.64
24 sh
$3,951.38
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.